Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...

CHICAGO (Reuters) -Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still ...

A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...

Novo trials test Rybelsus for Alzheimer's cognitive decline Experts uncertain on GLP-1 impact on Alzheimer's brain pathology Success could boost Novo shares by up to 10%, analysts say Nov 20 (Reuters) ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) sits squarely at the center of Monday's shock. The fund's top weights — Eli Lilly at 18.72% and Novo Nordisk at 13.23% — mean that more than ...

India emerges as key battleground for GLP-1 drugs Novo races to counter Lilly's Mounjaro in India Generics loom as semaglutide patent expiry nears in 2026 HYDERABAD, India, Dec 3 (Reuters) - Danish ...

Novo Nordisk A/S’s next-generation diabetes shot lowered patients’ blood sugar and helped them lose weight in a study that may be a positive sign for the embattled drugmaker’s future portfolio. When ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...